Cyclobenzaprine - NDSRI's
References
FAQ's
References
- Wendler, Norman L., 5 -(ω-Aminoalkylidene)-5H-dibenzo[a,d]cycloheptenes, BE633316A, June 6, 1963, Merck & Co., Inc. (https://worldwide.espacenet.com/patent/search/family/000200918/publication/BE633316A?q=BE633316)
- Heinitz, Maxine L., Determination of cyclobenzaprine in tablets by high-performance liquid chromatography, Journal of Pharmaceutical Sciences, Volume: 71, Issue: 6, Pages: 656-8, 1982. DOI: (10.1002/jps.2600710612)
Frequently Asked Questions
2. How do we detect the Cyclobenzaprine impurities in the drug product?
RP-HPLC method can detect the Cyclobenzaprine impurities in the drug product.
3. What causes the degradation of Cyclobenzaprine?
Oxidation of the double bonds and tertiary amine group causes the degradation of Cyclobenzaprine.
4. Which analytical method determines the presence of Cyclobenzaprine degradation products in the drug product?
LC-MS is the analytical method that determines the presence of Cyclobenzaprine impurities in the drug product.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.